# Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

> **NCT03843528** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Johns Hopkins All Children's Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Mixed Phenotype Acute Leukemia
- Juvenile Myelomonocytic Leukemia

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Azacitidine Injection

## Key facts

- **NCT ID:** NCT03843528
- **Lead sponsor:** Johns Hopkins All Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-01
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03843528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03843528, "Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03843528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*